Clinical Trials Logo

Clinical Trial Summary

At present, cerebral vasospasm (cVS) is the main cause of delayed cerebral infarction (DCI), which leads to high disability and mortality rate after aneurysmal subarachnoid hemorrhage. As a consequence, the key of reducing DCI is to prevent cVS. But unfortunately, despite years of efforts, the prevention and treatment of cVS is still a major clinical dilemma and various ways of treatment are still being explored. Recent studies have shown that stellate ganglion block (SGB) can dilate cerebral vessels and alleviate the impact of existing cVS. However, there is no study to evaluate the effect of early application of SGB on the improvement and prevention of cVS after aSAH.


Clinical Trial Description

Cerebral vasospasm refers to the extensive segmental or diffuse contraction of cerebral vasculature after aSAH, and cerebral blood flow is significantly reduced, which can lead to delayed cerebral ischemia (DCI) or delayed ischemic neurological dysfunction (DIND). Past studies have shown that if cerebral vasospasm occurs in patients with aSAH, the proportion of ischemic brain injury can be as high as 20%-30%.Obviously, prevention and treatment of CVS are the key to reducing the disability and mortality of aSAH. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04691271
Study type Interventional
Source Beijing Tiantan Hospital
Contact Ruquan Han, M.D., Ph.D
Phone 8610-59976660
Email ruquan.han@gmail.com
Status Recruiting
Phase N/A
Start date July 1, 2021
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03209830 - Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Not yet recruiting NCT03271697 - Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage Phase 2/Phase 3
Recruiting NCT01098890 - Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT00692744 - Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH) N/A
Active, not recruiting NCT05738083 - Prediction Models for Complications, Disability, and Death in Patients With Aneurysmal Subarachnoid Hemorrhage
Completed NCT03754335 - SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture N/A
Completed NCT06076590 - Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study Phase 4
Recruiting NCT04548401 - Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
Terminated NCT04148105 - Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 4
Recruiting NCT06329635 - Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial N/A
Recruiting NCT02129413 - Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm N/A
Terminated NCT00487461 - Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06288659 - aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial N/A
Recruiting NCT05974111 - COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
Recruiting NCT03706768 - Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06284642 - Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK) Phase 4
Recruiting NCT01773200 - Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage N/A
Completed NCT02026596 - SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage N/A